"War on Drugs" is a American Myth

 Can Psychiatry “Re-Engage” with Pharma?                                                                                                  Sandra Steingard, M.D.

August 4, 2013

On August 1, Jeffrey Lieberman, M.D., the current President of the American Psychiatric Association,  wrote an open letter to Psychiatry News asking whether is was time for psychiatry to “re-engage with pharma”.

Dr. Lieberman asserts that although there are problems with the way the public perceives drug companies, he thinks it is time for psychiatry to re-evaluate  its connections to the industry.  He reports on a recent meeting of the American Psychiatric Foundation Corporate Advisory Council with representatives of 14 pharmaceutical companies.  He states these representatives “desired re-engagement with physicians and researchers, and most importantly, they understood that all such interactions must be transparent, rigorously monitored, and without conflict of interest.” It is clear from Dr. Lieberman’s post that this desire is mutual.                  www.madinamerica.com/2013/08/can-psychiatry-re-engage-with-pharma/